NEW YORK (GenomeWeb) – NanoString Technologies announced today that health insurer Humana has issued a positive coverage decision for its Prosigna Breast Cancer Gene Signature Assay.

The decision provides Humana's more than 13 million members with access to the test.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.